Westfuller Advisors’s AstraZeneca AZN Stock Holding History

Westfuller Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$31.8K	Buy	168 +2	+1%	+$376	0.01%	351
2026 Q1	$32.7K	Sell	166 -876	-84%	-$169K	0.01%	306
2025 Q4	$192K	Sell	1,042 -21	-2%	-$3.68K	0.08%	149
2025 Q3	$163K	Buy	+1,063	New	+$161K	0.07%	170

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Westfuller Advisors's AZN Position: Q2 2026 in Review

Westfuller Advisors increased its AstraZeneca (AZN) stake by 1.2% in Q2 2026, buying an estimated $376 and bringing the position to 168 shares worth $31.8K. The position accounts for 0.01% of the portfolio, ranked #351.

Westfuller Advisors first reported a position in AZN in Q3 2025 and has held it in 4 quarters since. The position peaked at $192K in Q4 2025. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Westfuller Advisors held 168 shares of AstraZeneca worth $31.8K as of Q2 2026.
Westfuller Advisors bought 2 AstraZeneca shares in Q2 2026, an estimated $376.
AstraZeneca made up 0.01% of Westfuller Advisors's portfolio in Q2 2026, its #351 holding.
Westfuller Advisors first reported a position in AstraZeneca in Q3 2025 and has held it in 4 quarters since.
Westfuller Advisors's AstraZeneca position peaked at $192K in Q4 2025.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Westfuller Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.